Paragon Care Valuation

Is PGC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PGC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PGC (A$0.5) is trading above our estimate of fair value (A$0.42)

Significantly Below Fair Value: PGC is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PGC?

Key metric: As PGC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PGC. This is calculated by dividing PGC's market cap by their current earnings.
What is PGC's PE Ratio?
PE Ratio	98.8x
Earnings	AU$8.38m
Market Cap	AU$744.89m

PGC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.3x
Enterprise Value/EBITDA	25.5x
PEG Ratio	2.8x

Price to Earnings Ratio vs Peers

How does PGC's PE Ratio compare to its peers?

The above table shows the PE ratio for PGC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	49.1x
ACL Australian Clinical Labs	28.9x	16.0%	AU$682.4m
NAN Nanosonics	82.8x	24.0%	AU$1.0b
PSQ Pacific Smiles Group	38.7x	16.3%	AU$311.2m
HLA Healthia	46.1x	n/a	AU$252.1m
PGC Paragon Care	98.8x	35.6%	AU$744.9m

Price-To-Earnings vs Peers: PGC is expensive based on its Price-To-Earnings Ratio (98.8x) compared to the peer average (36.5x).

Price to Earnings Ratio vs Industry

How does PGC's PE Ratio compare vs other companies in the Global Healthcare Industry?

11 Companies	Price / Earnings	Estimated Growth	Market Cap

11 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: PGC is expensive based on its Price-To-Earnings Ratio (98.8x) compared to the Global Healthcare industry average (20.6x).

Price to Earnings Ratio vs Fair Ratio

What is PGC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PGC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	98.8x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PGC's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PGC forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	AU$0.50	AU$0.49 -2.0%	6.1%	AU$0.52	AU$0.46	n/a	2
Nov ’25	AU$0.41	AU$0.49 +18.1%	6.1%	AU$0.52	AU$0.46	n/a	2
Oct ’25	AU$0.47	AU$0.49 +5.4%	6.1%	AU$0.52	AU$0.46	n/a	2
Sep ’25	AU$0.41	AU$0.49 +19.5%	6.1%	AU$0.52	AU$0.46	n/a	2

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

SDI

AU$122.4m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.02

22.9%

Doctor Care Anywhere Group

AU$25.7m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.065

-3.0%

32.7%

Nova Eye Medical

AU$36.6m

Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.

EYE

AU$0.16

3.2%

14.3%